A study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending dose of ASP0456 in non-elderly healthy subjects.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Masking
TRIPLE
Enrollment
32
Unnamed facility
Kantou, Japan
Pharmacokinetics of ASP0456 assessed by its plasma concentration change
Time frame: For 48 hours after dosing
Safety assessed by the incidence of adverse events, vital signs, 12-lead ECGs and labo tests
Time frame: For 48 hours after dosing
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.